版本:
中国

BRIEF-Novan reports positive topline results with SB208 in phase 2 trial

April 12 Novan Inc

* Novan reports positive topline results with SB208 in phase 2 trial

* Novan Inc - SB208 gel, at both 4% and 16% concentrations, demonstrated a statistically significant effect (p<0.05) versus vehicle in a clinical trial

* "Results from this phase 2 trial with SB208 confirm fungicidal activity of nitric oxide observed in our preclinical studies"

* Novan - Based on data from SB208 phase 2 dose-ranging trial, co will evaluate late stage development opportunities in superficial cutaneous fungal infections

* Novan - Will evaluate opportunities such as a phase 2 trial in patients with onychomycosis, to be initiated as early as second half of 2017 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐